ALGS Aligos Therapeutics, Inc.

NASDAQ
$1.66

Aligos Therapeutics, Inc. (ALGS) is expected to report earnings on February 5, 2027, before the market open. The consensus earnings estimate is a loss of $2.03 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -62.6% since its last earnings release on November 6, 2026.

Aligos Therapeutics, Inc. Beat Consensus Estimates
Friday, November 6, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 5
Friday · 8:00 AM ET
Earnings Whisper
-
vs ($2.03)
Rev est $2.87M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.58

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver diseases and viral infections.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.